Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.

MLA

Stader, Felix, et al. “Stopping Lopinavir/Ritonavir in COVID-19 Patients: Duration of the Drug Interacting Effect.” The Journal of Antimicrobial Chemotherapy, vol. 75, no. 10, Oct. 2020, pp. 3084–86. EBSCOhost, https://doi.org/10.1093/jac/dkaa253.

APA

Stader, F., Khoo, S., Stoeckle, M., Back, D., Hirsch, H. H., Battegay, M., & Marzolini, C. (2020). Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. The Journal of Antimicrobial Chemotherapy, 75(10), 3084–3086. https://doi.org/10.1093/jac/dkaa253

Chicago

Stader, Felix, Saye Khoo, Marcel Stoeckle, David Back, Hans H Hirsch, Manuel Battegay, and Catia Marzolini. 2020. “Stopping Lopinavir/Ritonavir in COVID-19 Patients: Duration of the Drug Interacting Effect.” The Journal of Antimicrobial Chemotherapy 75 (10): 3084–86. doi:10.1093/jac/dkaa253.